uniQure Q1 2023 Earnings Report
Key Takeaways
uniQure reported a net loss of $77.2 million for Q1 2023, with revenue increasing to $5.3 million compared to $1.8 million in the same period last year. The company's cash and cash equivalents totaled $315.3 million as of March 31, 2023.
Cash and cash equivalents and investment securities totaled $315.3 million as of March 31, 2023.
Revenue for the quarter was $5.3 million, up from $1.8 million in the same period in 2022.
Research and development expenses increased to $60.8 million.
Net loss for the quarter was $77.2 million, or $1.63 loss per ordinary share.
uniQure
uniQure
Forward Guidance
uniQure anticipates continued progress on the commercialization of HEMGENIX, enrollment of a third cohort of patients in the AMT-130 clinical trial for Huntington’s Disease in the U.S. in the second half of 2023, announcing one to two-years of follow up data from the U.S. Phase I/II clinical study of AMT-130 in the second quarter of 2023, presentation of clinical data from the lower-dose cohort for AMT-130 in the second half of 2023, submission of an investigational new drug application for Fabry disease in 2023, initiation of a Phase I/II clinical study of AMT-162 for the treatment of ALS in the second half of 2023, and submission of an investigational new drug application or initiation of a Phase I/II clinical study of AMT-260 for rTLE in the second half of 2023.